• Associate Professor, Faculty of Pharmacy, Université de Montréal
  • Co-Director, Montreal Cancer Consortium
  • Co-Holder, Jean-Guy Sabourin Chair
  • Researcher at the CRCHUM
  • Research member at the Montreal Cancer Institute

Research Angle

My laboratory has identified the CD73 enzyme, which generates extracellular adenosine, as a novel therapeutic target in immuno-oncology. We are studying the role of the adenosinergic pathway in oncology. We also study the mechanisms of resistance to anti-PD-1/L1 therapies.

Laboratory Team

  • Bertrand Allard, Ph.D., research associate
  • Sandra Pommey, M.Sc., research associate
  • Isabelle Cousineau, Ph.D., research assistant
  • Yacine Bareche, Ph.D., postdoctoral fellow
  • David Allard, Ph.D. Student
  • Chloé Thivierge, animal health technician

LinkedIn Profile


Recent Publications

  1. https://www.nature.com/articles/s41571-020-0382-2
  2. https://science.sciencemag.org/content/369/6510/1481.long
  3. https://jitc.bmj.com/lookup/pmidlookup?view=long&pmid=32098829
  4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682371/
  5. https://pubmed.ncbi.nlm.nih.gov/27872096/

Pubmed Page

Email Address for application



Dr. Stagg received his PhD from McGill University and pursued postdoctoral training in immuno-oncology in Melbourne, Australia from 2005 to 2010. Dr. Stagg’s work has identified the CD73-adenosine axis as a novel therapeutic target in immuno-oncology, leading to the development of targeted therapies currently in clinical trials. Dr. Stagg is a Canadian Institutes of Health Research Scholar and co-holder of the Jean-Guy Sabourin Pharmaceutical Chair in Women’s Health at the Université de Montréal.